The awareness gap looks different when you pay your own way

When you have no insurance, every new health idea arrives with a price tag attached before you even understand what it is. So when someone mentions a depression treatment you have never heard of, the first thought may not be "could this help?" but "what is this going to cost me to find out?"

That question sits at the center of this piece. Our survey reached 443 Midwest adults in June 2026, and one finding in particular deserves a closer look from the point of view of people who pay their own way.

What the survey found about awareness

We asked respondents whether they had heard of Spravato, the brand name for esketamine nasal spray. The answer was overwhelmingly no. Most, 73 percent, had never heard of it; 21 percent knew the name but not its meaning; and a mere 6 percent understood it.

Pollfish has finished validating these numbers, so they are final. They come from a broad sample of adults, not from people who were already seeking treatment.

We also asked about coverage. Nine percent of respondents, 39 people, said they were uninsured, and 85 percent of those uninsured respondents had never heard of Spravato. What follows is about what that finding means for anyone in that situation.

Why the gap costs more without coverage

For someone with insurance, not knowing a treatment's name is often fixed by a clinician who brings it up during a covered visit. The discovery is close to free.

Without insurance, discovery is where the costs start. A visit to ask a question costs money. A specialist consultation costs more. And the treatment options most visible online, the cash-pay ketamine clinics and the at-home ketamine companies, are exactly the ones built to sell directly to people who are paying out of pocket.

That creates a real risk. If you do not know that esketamine exists as a distinct, FDA-approved treatment, you may assume that whatever ketamine offer pops up first is the only version available.

Three things that share a name

• Esketamine (Spravato): This one comes as a nasal spray. Its FDA approvals cover adults whose depression has held out against treatment and adults whose major depression brings acute suicidal thoughts or behavior, and it is given only in certified health care settings, where staff monitor you for two or more hours after each dose.
• IV ketamine: Ketamine is FDA-approved as an anesthetic. Infusions for depression are off-label, meaning a clinician is using it for something the FDA has not approved. Clinics offering it commonly charge cash.
• At-home ketamine: Tablets or lozenges, often compounded, prescribed through telehealth and taken at home without a clinician present. This is also off-label, and the FDA has issued public warnings about the risks of unmonitored use.

None of these is right or wrong for everyone, and none should be chosen by price alone. But you deserve to know they are different before you spend money. A plain overview of the Spravato treatment explains the approved option.

What people said they would do instead of searching

Here is an encouraging part of the survey. Most people do not plan to navigate this alone. Fifty-six percent would begin with primary care. A psychiatrist would come first for 23 percent, and a do-it-yourself online search for just 12 percent.

And the recommendation that would move people most was their own doctor's, chosen by 74 percent, far ahead of a friend or relative at 18 percent and an ad at 2 percent. For uninsured respondents it was 67 percent.

Without insurance, many people also lack a regular doctor, and that finding can sting. But low-cost doors exist, and knowing them is the first step.

Low-cost doors to a clinician

• Community health centers. These federally funded clinics set fees by income, and many include behavioral health care. The federal health center locator at findahealthcenter.hrsa.gov lists them by ZIP code.
• Community mental health centers. Many states fund centers that see patients whatever they can afford. Your state's mental health department website usually lists them.
• Check whether you now qualify for Medicaid. Income limits changed in many states when Medicaid expanded. Missouri, for example, opened eligibility to many working-age adults. It takes minutes to check on your state's Medicaid site or through HealthCare.gov.
• Marketplace coverage. If you lost a job, moved, or had another qualifying life change, you may be able to enroll outside the usual open enrollment window. Premium subsidies can make plans cheaper than people expect.
• Manufacturer support. Drug makers often run patient assistance programs. Ask any clinic you visit whether assistance exists for the specific medication being discussed.

What people told us they would trade

We asked respondents to choose between insured care with more steps and self-pay for a quicker, simpler start. Just over half chose coverage, 23 percent chose paying themselves, and another 26 percent were unsure. That split is a useful mirror. Paying yourself can buy speed, but for a treatment that involves many sessions over weeks and months, getting covered first is often worth considering even if it takes longer.

Questions to ask before paying anyone

• Is this esketamine, IV ketamine, or at-home ketamine?
• Is this treatment FDA-approved for my condition, or used off-label?
• What is the full cost for a complete course, not just a single session?
• Who evaluates me before treatment, and who monitors me during it?
• What happens if I have a bad reaction?

A trustworthy provider answers every one of these plainly. If you get vagueness about cost or safety, keep looking.

A limit worth stating

This is survey research, not medical guidance. It cannot tell you whether any form of ketamine or esketamine suits you. Only a clinician who knows your health history can do that, and some people are not good candidates at all.

Money trouble and depression feed each other, and that combination can make things feel hopeless. When thoughts of suicide show up, 988 is the number: the Suicide and Crisis Lifeline takes a text or a call with no charge, no insurance check, and no appointment, and veterans can press 1.

Methodology

Our survey stayed live on the Pollfish consumer panel through the June 23, 2026 close. It drew 443 respondents between 18 and 64 living in Oklahoma, Ohio, Minnesota, Iowa, Missouri, Kansas, Illinois, Indiana, Nebraska, and Wisconsin. Results are whole-sample apart from the uninsured group noted above; the coverage question allowed multiple answers; and each figure is from the validated final export. The research was commissioned, and financed, by our publisher.